RxDoctor Payments Data

Daniel Kimple, MD

Neurology · Quincy, ILNPI 1699030551

Payments from drug & device makers

$17,080in general payments, 2019–2025

Across 1,008 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$1K
  • UCB, Inc.$1K
  • Amgen$761
  • Harmony Biosciences LLC$749
  • Bristol Myers Squibb$700
  • plus $10K from 52 others

What the payments were for

  • Speaking & faculty fees$390%
  • Travel & lodging$3282%
  • Food & beverage$16,68598%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$2,388
Livanova USA, Inc.21$1,190
UCB, Inc.70$1,056
Amgen(2 entities)51$761
Harmony Biosciences LLC53$749
Bristol Myers Squibb71$700
SK Life Science, Inc.37$694
Neurocrine Biosciences, Inc.29$602
Lilly USA, LLC33$568
Acadia Pharmaceuticals Inc37$538
EMD Serono, Inc.22$495
Pfizer26$456
Biogen25$429
Teva Pharmaceuticals USA, Inc.29$380
Eisai Inc.24$375
Neurelis, Inc.21$360
Sanofi20$329
Supernus Pharmaceuticals, Inc.25$324
Genentech USA, Inc.14$324
Lundbeck LLC15$305
Argenx US, Inc.15$286
Sumitomo Pharma America, Inc.16$274
Novartis14$273
Biohaven Pharmaceuticals, Inc.28$268
Biohaven Pharmaceutical Holding Company Ltd.15$200
Takeda Pharmaceuticals U.S.A., Inc.5$191
Alnylam Pharmaceuticals Inc.5$190
Jazz Pharmaceuticals Inc.10$184
Medtronic(2 entities)8$163
Sunovion Pharmaceuticals Inc.9$148
Acorda Therapeutics, Inc8$147
Adamas Pharmaceuticals, Inc.8$133
Abbott6$128
Boston Scientific5$122
Amneal Pharmaceuticals LLC7$111
Avion Pharmaceuticals3$103
GE HealthCare6$99
Merz Pharmaceuticals, LLC5$96
Catalyst Pharmaceuticals, Inc.4$93
Ipsen Biopharmaceuticals, Inc4$91
Upsher-smith Laboratories LLC6$91
Kyowa Kirin, Inc.6$87
Tanabe Pharma America, Inc.4$67
Cycle Pharmaceuticals Inc3$66
Impel Pharmaceuticals Inc.4$63
Averitas Pharma Inc.3$60
Otsuka America Pharmaceutical, Inc.3$46
Avanir Pharmaceuticals, Inc.2$44
Grifols USA, LLC2$44
CSL Behring1$32
Vanda Pharmaceuticals Inc.2$32
E.r. Squibb & Sons, L.L.C.2$25
Johnson & Johnson1$23
AstraZeneca1$22
MDD US Operations, LLC1$16
Greenwich Biosciences, Inc.1$16
Electromed, Inc.1$13
Arbor Pharmaceuticals, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,080 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$348,142
Medicare patients
599
Services billed
25,698

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone12$170,958
Aimovig AutoinjectorErenumab-Aooe43$31,484
Emgality PenGalcanezumab-Gnlm33$22,235
RytaryCarbidopa/Levodopa18$19,681
RexultiBrexpiprazole12$17,181
Nurtec OdtRimegepant Sulfate14$16,115
Memantine Hcl475$15,255
QuliptaAtogepant13$13,640
Emgality SyringeGalcanezumab-Gnlm15$10,553
Carbidopa-LevodopaCarbidopa/Levodopa397$7,945
Lacosamide26$7,837
EliquisApixaban12$6,867
TegretolCarbamazepine12$5,345
Levetiracetam137$4,531
Gabapentin365$4,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Eliquis$456$22,98226 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$111$20,61634 claims
Otsuka America Pharmaceutical, Inc.Rexulti$46$17,18112 claims
AbbVieQulipta$2,388$13,64013 claims
Upsher-smith Laboratories LLCTopiramate$91$37861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.

Other neurology in Quincy

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →